CCM
PACB icon

Cinctive Capital Management’s Pacific Biosciences PACB Stock Holding History

Cinctive Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-80,000
Closed -$464K – 502
2022
Q3 		$464K Buy
+80,000
New +$459K 0.02% 394

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Cinctive Capital Management's PACB Position: Q3 2023 in Review

Cinctive Capital Management sold out of Pacific Biosciences (PACB) in Q3 2023, closing a stake of 149,798 shares — an estimated $1.99M sold.

Cinctive Capital Management first reported a position in PACB in Q2 2023 and held it in 1 quarter. The position peaked at $1.99M in Q2 2023. 274 funds tracked by Wall St. Rank hold PACB as of Q3 2023.

  • Cinctive Capital Management reported no remaining Pacific Biosciences position as of Q3 2023 after selling out during the quarter.
  • Cinctive Capital Management sold 149,798 Pacific Biosciences shares in Q3 2023, an estimated $1.99M.
  • Cinctive Capital Management first reported a position in Pacific Biosciences in Q2 2023 and held it in 1 quarter.
  • Cinctive Capital Management's Pacific Biosciences position peaked at $1.99M in Q2 2023.
  • 274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2023.

Based on Cinctive Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.